IfW

Patent Application Attorney Docket No.PC23199A

Thereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this **28th** day of September, 2004.

gnature of person mailing)

Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Steven W. Collier, et al.

APPLICATION NO.: 10/636,013 : Examiner:

FILING DATE: August 6, 2003 : Group Art Unit: 1616

TITLE: STABLE NON-DIHYDRATE

AZITHROMYCIN ORAL SUSPENSIONS

Hon. Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

. .

Respectfully submitted,

Date: 27 September 2004

Scott Alexander McNeil Attorney for Applicant(s)

Reg. No. 37,185

Pfizer Inc.

Patent Department, MS 8260-1611 Eastern Point Road Groton, Connecticut 06340 (860) 686-1848

#71984 v1 - PC23199A INFORMATION DISCLOSURE STATEMENT

INFOF	MATI	SATELA P	CLOSI	UBE CI	TATION	Тат	TY. DOC	CKFT N	O. PC2319		SERIAL NO	. 10/63	6.013	
							PLICAN			ollier, et al.	02111112110		0,010	
(Use several sheets if necessary)				-	FILING DATE August 6, 2003				GROUP 1616					
			-						UMENTS					-
EXAMINER INITIAL	DOCUMENT NUMB			MBER			DATE	NAME	CLASS	SUBCLASS	FILING IF APPR	DATE OPRIATE		
	us	4	4	7	4	7	6	8	10/2/84	Bright	424	180		
	us	6	3	6	5	5	7	4	4/2/02	Singer, et a	ıl. 514	29		
	US	6	2	4	5	9_	0	3	6/12/01	Karimian, et	al. 536	7.4		
	US	6	2	6	8	4	8	9	7/31/01	Allen, et al	. 536	7.4		•
	us	4	9	6	3	5	3	1	10/16/90	Remingtor	514	29		
	US	5	6	0	5	8	8	9	2/25/97	Curatolo, et	al. 514	29		
						FORE	IGN PAT	ENT D	OCUMEN	TS		,		
		DOCUMENT NUMBER							DATE COUNTRY		CLASS	SUBCLASS	TRANS	LATION
			1	T	1		<u> </u>	T					YES	NO
	wo	0	4	0	0	8	6	5	12/31/03	Internationa	al C07H	17/08		ļ
	wo	0	0	5	7	8	8	6	5/10/00	Internationa	al A61K	31/70	х	
			ОТН	ER DO	CUMEN	TS (In	cluding A	Author,	Title, Date,	Pertinent Pa	ges, Etc.)			
		Zheng Li, et al., U.S. Patent Application Serial Number (USSN) 10/152,106, Publication No. 2003-0162730A1, published on 8/28/00								8/03				
		Ofner, C., et al., "Suspensions", FMC BioPolymer, Section 9, pp.1-22 (2000)												
		Dell, S., et al., "Avicel® RC/CL, Microcrystalline Cellulose and Carboxymethylcellulose Sodium, NF, BP", FMC BioPolymer, Section 14. pp. 1-27 (2001)												
		Weissbuch, I, et al., "Understanding and Control of Nucleation, Growth, Habit, Dissolution and Structure of Two- and Three-Dimensional Crystals Using 'Tailor-Made' Auxiliaries", <i>Acta Cryst.</i> , Vol. B51, pp. 115-148 (1995)												
		Ebian, A., et al., "Effect of additives on the kinetics of interconversation of sulphamethoxydiazine crystal forms", J. Pharm. Pharmac Vol. 25, pp. 13-20 (1973)												
		Miyazaki, S., "Effect of Additives on the Polymorphic Transformation of Chlortetracycline Hydrochloride Crystals", <i>Chem. Pharm. Bull.</i> , Vo. 24(9), pp. 2094-2101 (12976)												
		Ziller, K.H., et al., "Control of Crystal Growth in Drug Suspensions", Pharm. Ztg. Wiss., NR. 4-3./135. pp. 147-152 (1990)												
		Shefter, E., "Dissolution Behavior of Crystalline Solvated and Nonsolvated Forms of Some Pharmaceuticals", <i>Journal of Pharmaceutical Sciences</i> , Vol. 52., No. 8, pp. 781-791 (1963)												
		Otsuka, M., et al., "Effect of binders on polymorphic transformation kinetics of carbamazepine in aqueous solution", Colloids and Surfaces B; Biointerfaces, Vol. 17, pp. 145-152 (2000)												
		Horn, Haupt	D., et al.,	"Interacti ium der B	on betwee	en polyv	inylpyrrolid schaft, D-6	one and (drugs: an app 30-100	oraisal of its signi	ficance for GI dr	ug absorptio	n",	

INFORMATI	ON DISCLOSURE CITATION	ATTY. DOCKET NO. PC23199A	SERIAL NO.	10/636,013							
(Use se	everal sheets if necessary)	APPLICANT Steven W. Collier, et al.									
, ·		FILING DATE August 6, 2003	GROUP	1616							
OIPE	Johnson, B., et al., "Effects of Surfac 17, pp. 325-342 (1986)	tants and Polymers on Advancing and Receding (Contact Angles", Colloid	s and Surfaces, Vol.							
SEP 3 0 2004.	Elworthy, P., et al., "The Surface Ten Mofmation", Journal of Colloid and In	nsion of Sodium Dodecylsulfate Solutions and the nterface Science, Vol. 21, pp. 331-347 (1966)	Phase Separation Mode	el of Michelle							
SEP 3 0 2004	Askar, A., "A Review on Sweeteners'	", Nutrition, Vol. 12, Nr. 11, pp. 706-712 (1988)									
	Parsons, D., "Carboxymethylcellulos	e Sodium", Handbook of Pharmaceutical Excipien	ts, 3 rd Edition, pp. 87-90								
	Goskonda, S.R., et al., "Cellulose Acetate Phthalate", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 99-101 Malick, A.W., "Docusate Sodium", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 188-190										
Hogan, J.E., "Coloring Agents", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 146-153											
	Harwood, R.J., "Hydroxypropyl Cellul	arwood, R.J., "Hydroxypropyl Cellulose", <i>Handbook of Pharmaceutical Excipients</i> , 3 rd Edition, pp. 244-248									
	nts, 3 rd Edition, pp. 252-	255									
	139										
	Russell, G., et al., "Saccharin", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 454-456										
	dition, pp. 457-459										
	Behn, S., "Sodium Lauryl Sulfate", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 487-489										
	Behn, S., "Sodium Phosphate, Dibasic", Handbook of Pharmaceutical Excipients, 3 rd Edition, Sections 12-19, p.494										
	Armstrong, N.A., et al., "Sucrose", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 539-543										
	Daskalakis, S.A., "Xanthan Gum", Handbook of Pharmaceutical Excipients, 3 rd Edition, pp. 599-601										
	Handbook of Pharmaceutical Additive	es, pp. 120; 214; 351; 484-485; 557; 558; 610; 63	9; 713-714								
EXAMINER		DATE CONSIDERED									
EXAMINER: Initial if re	ference considered, whether or not citation is in confe	ormance with MPEP 609; Draw line through citation if not in confor									

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE